Skip to content
Study details
Enrolling now

Multitracer [18F]Fluciclovine and 18F-FDG PET, and Advanced MRI for Metabolic Profiling of Glioblastoma

Abramson Cancer Center at Penn Medicine
NCT IDNCT06613841ClinicalTrials.gov data as of Apr 2026
Phase

EARLY_PHASE1

Target enrollment

15

Study length

about 1.7 years

Ages

18+

Locations

2 sites in PA

What this study is about

Researchers are testing a treatment called Fluciclovine F18 to see how it affects glioblastoma tumors. The trial will compare the results from imaging tests like PET scans and advanced MRIs with lab tests on tumor tissue to understand how these tumors use energy (glucose, lactate) and amino acids (glutamine/glutamate).

Simplified from trial records by PatientMatch.

What you may be asked to do

  • 1.Take Fluciclovine F18

Participation Burden

What's physically and logistically required of participants.

Logistics & Travel
In-person visits

Requires travel to a study site

Physical Intervention
Standard

How treatment is administered

Treatment Assignment
All receive treatment

Everyone gets the investigational treatment.

Extracted study details

Pulled from the trial record to show what is being tested and what the study is measuring.

Drug classes

Diagnostic Agent (Positron Emitting Activity)

Endpoints

Primary: Uptake Values (SUV)

Body systems

Neurology, Oncology